Palantir's AI Surge: What Investors Need to Know After Q2 Earnings
Palantir's Q2 earnings show a strong 16% share price increase and highlight growing demand for enterprise AI.
Pfizer's Strategic Shift: Navigating Beyond Covid Revenue
Pfizer's recent Q2 earnings reflect a pivot to non-Covid products as Covid revenue expectations are reduced.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Sunshine Biopharma's New Drug Approval: A Strategic Move into Women's Health
Sunshine Biopharma's approval of a generic drug opens doors to a lucrative women's health market worth $5.2 billion.
Palantir's AI Surge: What It Means for Tech Investors
Palantir's shares rose 16% after strong Q2 earnings, indicating robust demand for AI solutions.
Pfizer's Q2 Earnings Beat: A Post-Pandemic Perspective
Pfizer's Q2 earnings exceeded expectations, signaling strong performance from non-COVID products amid adjusted revenue f…
Visa's $2.4 Billion Acquisition of BioCatch: A Strategic Move in Fintech
Visa's acquisition of BioCatch for $2.4 billion is a strategic response to rising AI-driven fraud threats in the fintech…
Eli Lilly's FDA Approval: A Catalyst for Market Momentum
Eli Lilly's recent FDA approval sparks momentum in LLY's stock and the broader market, with the Dow rising significantly…
Curium and Lantheus Merger: A Game-Changer for Radiopharmaceuticals
Curium and Lantheus' $8 billion merger could reshape the radiopharmaceutical landscape and offer significant benefits to…
Integer Holdings to Go Private: Analyzing the KKR Acquisition
Integer Holdings is set to be acquired by KKR for $5.7 billion, raising questions about the future of the medical device…
Supernus and Indivior Merger: A New Era for CNS Biopharmaceuticals
Supernus and Indivior's all-stock merger could reshape the CNS biopharmaceutical landscape significantly.
Curium's $8 Billion Acquisition of Lantheus: What it Means for Investors
Curium's $8 billion acquisition of Lantheus could reshape the radiopharmaceutical landscape. Here's what investors need …